Table 1 Demographics, clinicopathologic characteristics and outcomes for the BR36 cohort (all enrolled patients)
From: ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Characteristic | Number (%) |
|---|---|
Sex | |
Female | 26 (52.0) |
Male | 24 (48.0) |
Race | |
White | 41 (82.0) |
Black | 2 (4.0) |
Asian | 4 (8.0) |
Not Reported | 3 (6.0) |
Agea | |
<65 years | 22 (44.0) |
≥65 years | 28 (56.0) |
ECOG PS | |
0 | 12 (24.0) |
1 | 38 (76.0) |
Smoking status (current) | |
Yes | 12 (24.0) |
No | 37 (74.0) |
Missing | 1 (2.0) |
Smoking history | |
>100 cigarettes during lifetime | 49 (98.0) |
Missing | 1 (2.0) |
Prior systemic therapy | |
No | 46 (92.0) |
Yes | 4 (8.0) |
Prior radiation | |
No | 27 (54.0) |
Yes | 23 (46.0) |
Prior surgery | |
No | 1 (2.0) |
Yes | 49 (98.0) |
Stage | |
Stage IIIb | 1 (2.0) |
Stage IV | 49 (98.0) |
Histology | |
Adenocarcinoma | 38 (76.0) |
Squamous cell carcinoma | 6 (12.0) |
Other | 6 (12.0) |
PD-L1 expression | |
≥50% TPS | 48 (96.0) |
1–49% | 2 (4.0) |
RECIST response | |
CR/PR | 16 (32.0) |
SD/PD | 34 (68.0) |
ctDNA response | |
mR | 15 (42.9) |
mPD | 20 (57.10) |
